Androgen receptor (AR)-targeted therapies, including AR agonists and AR antagonists, have shown promising results in clinical trials for breast cancer patients, and combinations of AR-targeted therapies with other reagents (eg. PI3K inhibitor) have been studied to overcome resistance to AR-targeted therapies13. Here, AR is linked to breast cancer.